These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11774836)

  • 21. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scientists find some genes a bad omen for anti-HIV drug.
    Stephenson J
    JAMA; 2002 Apr; 287(13):1637. PubMed ID: 11926874
    [No Abstract]   [Full Text] [Related]  

  • 23. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 26. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
    Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
    Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
    Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient.
    Soler Palacin P; Aramburo A; Moraga FA; Cabañas MJ; Figueras C
    Pediatr Infect Dis J; 2006 Apr; 25(4):382. PubMed ID: 16568000
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic cough induced by abacavir apart from a context of hypersensitivity.
    Peyrière H; Mauboussin JM; Arnaud A; Rouanet I; Vincent D
    Allerg Immunol (Paris); 2002 Dec; 34(10):359-60. PubMed ID: 12575618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
    Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
    Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
    García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
    AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
    [No Abstract]   [Full Text] [Related]  

  • 34. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.
    El-Sahly HM
    AIDS; 2004 Jan; 18(2):359-60. PubMed ID: 15075569
    [No Abstract]   [Full Text] [Related]  

  • 35. Heart attack risk with abacavir and didanosine.
    AIDS Patient Care STDS; 2008 Apr; 22(4):346-7. PubMed ID: 18434947
    [No Abstract]   [Full Text] [Related]  

  • 36. Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative.
    Calza L; Rosseti N; Biagetti C; Pocaterra D; Colangeli V; Manfredi R
    Int J STD AIDS; 2009 Apr; 20(4):276-7. PubMed ID: 19304978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug hypersensitivity in HIV.
    Phillips E; Mallal S
    Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
    Fontaine C; Guiard-Schmid JB; Slama L; Essid A; Lukiana T; Rondeau E; Pialoux G
    AIDS; 2005 Nov; 19(16):1927-8. PubMed ID: 16227807
    [No Abstract]   [Full Text] [Related]  

  • 39. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
    Wolbach J; Capoccia K
    Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
    [No Abstract]   [Full Text] [Related]  

  • 40. Warning against rechallenge with abacavir.
    AIDS Patient Care STDS; 1998 Mar; 12(3):229. PubMed ID: 11361938
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.